Question follow-through · 30888
Pancreatic Enzyme Replacement Therapy
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the supply of Creon; and what support his Department is providing to patients who are not able to use alternative medicines.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 11 Feb 2025
- Target answer date
- 13 Feb 2025
- Answer
- 17 Feb 2025 · 6 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- Lung Cancer: Screening · 13 Feb 2025
- Functional Neurological Disorder: Health Services · 14 Oct 2025
- ME/CFS: Health Services · 27 Apr 2026
- Dementia: Health Services · 3 Jun 2026
- Restless Legs Syndrome: Drugs · 5 Jun 2026
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
11 Feb 2025
Question tabled
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the supply of Creon; and what support his Department is providing to patients who are not able to use alternative medicines.
13 Feb 2025
Target answer date
Date supplied by the official written-questions record.
17 Feb 2025
Answer published
The Department continues to engage with suppliers of Creon and other pancreatic enzyme replacement therapies (PERT) to boost production to mitigate the supply issue. The supplier of Creon expects to receive increased quantities for 2025. Suppliers of alte...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Lung Cancer: Screening
13 Feb 2025 · To ask the Secretary of State for Health and Social Care, if he will take steps to extend eligibility for NHS lung screening programmes to include people with a history of occupational exposure to (a) asbestos, (b) coal dust and (c) other hazardous substa
Functional Neurological Disorder: Health Services
14 Oct 2025 · To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure equitable access England to (a) diagnosis, (b) treatment and (c) specialist rehabilitation services for patients with Functional Neurological Disorder.
ME/CFS: Health Services
27 Apr 2026 · To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure that integrated care boards are held accountable for commissioning services for those with very severe ME/CFS the absence of a national specialise
Dementia: Health Services
3 Jun 2026 · To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that people with complex dementia needs, including those requiring one-to-one support, can access safe and suitable care placements following discharge
Restless Legs Syndrome: Drugs
5 Jun 2026 · To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that patients prescribed dopamine agonists are informed about the risk of impulse control disorders.
Drugs: Side Effects
10 Jun 2026 · To ask the Secretary of State for Health and Social Care, how many Yellow Card reports have (a) listed pramipexole, ropinirole, rotigotine and cabergoline as a suspected medicine and (b) included any reaction term relating to impulse control disorders, in
Drugs: Side Effects
10 Jun 2026 · To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of patients exposed to dopamine agonists for (a) Parkinson’s disease and (b) restless legs syndrome; and what comparison the Department has made
Drugs: Side Effects
10 Jun 2026 · To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the extent of under-reporting of dopamine agonist-related impulse control disorders to the Yellow Card scheme; and what steps it is taking to improv
Drugs: Side Effects
10 Jun 2026 · To ask the Secretary of State for Health and Social Care, what data his Department and the Medicines and Healthcare products Regulatory Agency holds on how many and what proportion of patients develop withdrawal symptoms, including dopamine agonist withdr
Drugs: Side Effects
10 Jun 2026 · To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the typical duration and severity of withdrawal symptoms associated with dopamine agonist dose reduction or discontinuation; and how those outcomes vary b
Drugs: Side Effects
10 Jun 2026 · To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number and proportion of patients who, having developed impulse control disorders while taking dopamine agonists and attempted withdrawal, subsequently
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential financial impact of dopamine agonist-related impulse control disorders on those experiencing such disorders, including through (a) gambling-